# Non-profit, open-licence lentiviral vectors and producer cell lines for CAR-T

Source: https://onco.cc/ideas/idea-reg-open-source-lentiviral-vectors/  
OnCo record `idea-reg-open-source-lentiviral-vectors` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The engineered virus that delivers the CAR gene costs tens of thousands of dollars per patient and is controlled by a few suppliers. A non-profit supplier with open licences would cut that cost sharply.

## Summary

Vector is often the single largest material cost in autologous CAR-T and a frequent cause of manufacturing delay; capacity is concentrated among a few contract suppliers and licences are restrictive. Caring Cross and several academic centres have shown that non-profit vector production can supply clinical programmes at a fraction of the cost. The proposal is a foundation-funded vector consortium with stable producer cell lines, a shared plasmid bank for common CARs (CD19, BCMA, CD22) under open licences for non-commercial and low-income-country use, and GMP production at cost.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Consortium vector supplied at cost reduces vector cost per CAR-T dose to below $5,000 and enables at least ten new academic or LMIC CAR-T programmes to reach the clinic within five years.
- Rationale: Vector production is a mature process whose price reflects concentration and licensing more than inherent cost; stable producer lines remove the plasmid transfection step that drives variability and expense.
- Proposed test: Fund the consortium to produce GMP vector for three academic CD19 programmes, audit cost per dose and release success rate against commercial contract supply, and count new programmes enabled.
- Maturity: early-clinical
- Actor: philanthropy

## Sources

- Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018): https://doi.org/10.1001/jamaoncol.2018.0977

## Connected records

- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Most of the world has almost no cancer care](https://onco.cc/bottlenecks/b-global-access/)
- key papers: [Total Costs of Chimeric Antigen Receptor T-Cell Immunotherapy](https://onco.cc/key-papers/paper-hernandez-jama-oncol/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-open-source-lentiviral-vectors.json